Association of FEV1%pred with RFS and OS in operable patients with early-stage NSCLC
| Incidence rate/1000 person-years (95% CI) | IRD/1000 person-years (95% CI) | HR (95% CI) | P value | ||
|
FEV1 <82%pred
(n=234) | FEV1 ≥82%pred (n=541) | ||||
| Crude outcome* | |||||
| Relapse or death (n=202) | 119 (94 to 144) | 65 (53 to 76) | 54 (27 to 82) | 1.84 (1.39 to 2.43) | <0.001 |
| Death (n=112) | 66 (49 to 87) | 32 (24 to 41) | 34 (14 to 54) | 2.09 (1.44 to 3.02) | <0.001 |
| Weighted outcome† | |||||
| Relapse or death | 110 (79 to 141) | 71 (47 to 95) | 39 (25 to 78) | 1.55 (1.14 to 2.09) | 0.007 |
| Death | 57 (38 to 83) | 38 (23 to 59) | 19 (2 to 41) | 1.50 (1.01 to 2.23) | 0.04 |
*Crude and weighted outcomes represent the results estimated before applying propensity score overlap weighting to adjust for covariates.
†Crude and weighted outcomes represent the results estimated after applying propensity score overlap weighting to adjust for covariates.
FEV1, forced expiratory volume in 1 s; IRD, incidence rate difference; NSCLC, non-small cell lung cancer; OS, overall survival; RFS, relapse-free survival.